Physician profile
Craig Lampert
NPI 1063403509
$3,449.42
in general payments reported to CMS, 2019-2025
42 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $126 · 2021: $239 · 2022: $1,535 · 2023: $667 · 2024: $351 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $1,000.00 | 2022 | |
| Celgene Corporation | $274.07 | 2019-2023 | Reblozyl |
| Daiichi Sankyo INC. | $223.09 | 2021-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $151.99 | 2020-2023 | Xpovio |
| Exelixis INC. | $128.47 | 2022 | |
| Epizyme, INC. | $125.00 | 2022 | |
| Blueprint Medicines Corporation | $124.61 | 2023-2025 | Ayvakit |
| Amgen INC. | $103.78 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.98 | 2023 | Opdivo |
| Pfizer INC. | $82.27 | 2019-2025 | |
| Mirati Therapeutics, INC. | $76.70 | 2023-2024 | Krazati |
| Glaxosmithkline, LLC. | $72.79 | 2021-2025 | Ojjaara |
| Janssen Scientific Affairs, LLC | $70.51 | 2019-2020 | |
| Aveo Pharmaceuticals, INC. | $68.92 | 2024-2025 | |
| Janssen Biotech, INC. | $53.49 | 2023-2025 | Darzalex |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.23 | 2023-2025 | Orgovyx |
| Puma Biotechnology, INC. | $50.89 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $48.73 | 2024-2025 | Keytruda, Lynparza |
| Abbvie INC. | $47.31 | 2019-2024 | |
| Incyte Corporation | $45.86 | 2020-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $44.34 | 2020-2021 | |
| Caris Mpi, INC. | $40.22 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $39.92 | 2021-2023 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $36.90 | 2024-2025 | Cosela, Monoferric |
| Novartis Pharmaceuticals Corporation | $31.42 | 2019-2023 | |
| Emd Serono, INC. | $29.21 | 2023 | Bavencio, Tepmetko |
| Seagen INC. | $28.11 | 2019-2023 | Padcev |
| Array Biopharma INC | $26.11 | 2024 | Talzenna, Inlyta, Xtandi |
| Myriad Genetic Laboratories, INC. | $24.23 | 2025 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $23.47 | 2025 | |
| Genmab U.S., INC. | $23.05 | 2025 | Epkinly |
| Deciphera Pharmaceuticals INC. | $22.69 | 2025 | Qinlock, Romvimza |
| Adc Therapeutics America, INC. | $21.19 | 2023 | |
| Genentech USA, INC. | $20.26 | 2024 | Venclexta |
| Eisai INC. | $20.06 | 2023 | |
| Astellas Pharma US INC | $19.52 | 2025 | Padcev |
| Octapharma USA, INC. | $17.11 | 2024 | Panzyga |
| Geron Corporation | $17.06 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.92 | 2024 | Libtayo |
| Amneal Pharmaceuticals LLC | $16.60 | 2025 | Alymsys |
| Alexion Pharmaceuticals, INC. | $16.34 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Lampert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.